Novo Nordisk A/S

Leading Practices

  • Novo Nordisk is among the highest performing companies in the area of innovative approaches to addressing ATM challenges.
  • The company’s ATM program priorities are determined by and developed in close collaboration with global health institutions.
  • The company continues to expand the breadth of its equitable pricing programs for diabetes and has implemented ‘pilot’ schemes to ensure the equitable prices are passed on to patients.
  • Novo Nordisk has undertaken significant activities through the “Changing Diabetes” umbrella and its World Diabetes Foundation, both of which aim at the “prevention and treatment of diabetes worldwide”.

 

Changes compared to Index 2008

  • Novo Nordisk’s “Changing Global Access to Diabetes Care” strategy was implemented in 2008 with the aim of making the company’s diabetes related access programs more sustainable, global and affordable
  • In April 2008, the company donated a license for its small molecule compound library for NTD screening to an Index Country institution, the National Center for Drug Screening (NCDS), at the Chinese Academy of Sciences. It does not hold patent rights on any product developed from the library.
  • The firm has a partnership with the Danish Institute of Human Rights and Transparency International to develop a new methodology for supply chain mapping in the Index Countries.

 

Suggested Areas for Improvement

  • The company does not undertake adaptive R&D to address specific needs of populations living in Index Countries, e.g. heat-stable products, simple delivery devices, or Fixed Dose Combinations (FDCs).
  • The company makes little disclosure on its intra-country tiered pricing programs that target specific groups (migrants, children and the poor).
  • The company has limited activities aimed at increasing local capacity in the Index Countries.
  • ""
Home » Stakeholders » Originator Pharmaceuticals